US 12,453,775 B2
Composition, for prevention or treatment of cancer disease, comprising cytotoxic T cells activated by T helper cell-derived extracellular vesicles as active ingredient
Moon-Chang Baek, Daegu (KR); Kyungmoo Yea, Daegu (KR); Do Kyung Jung, Daegu (KR); Suyeon Ryu, Daegu (KR); Sang Hee Shin, Busan (KR); and In Seong Jung, Daegu (KR)
Assigned to KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, Daegu (KR); and DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY, Daegu (KR)
Appl. No. 17/766,745
Filed by KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, Daegu (KR); and DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY, Daegu (KR)
PCT Filed Sep. 18, 2020, PCT No. PCT/KR2020/012619
§ 371(c)(1), (2) Date Apr. 6, 2022,
PCT Pub. No. WO2021/071126, PCT Pub. Date Apr. 15, 2021.
Claims priority of application No. 10-2019-0126173 (KR), filed on Oct. 11, 2019; and application No. 10-2020-0118557 (KR), filed on Sep. 15, 2020.
Prior Publication US 2024/0091355 A1, Mar. 21, 2024
Int. Cl. A61K 40/42 (2025.01); A61K 40/11 (2025.01); A61P 35/00 (2006.01); C12N 5/0783 (2010.01)
CPC A61K 40/428 (2025.01) [A61K 40/11 (2025.01); A61K 40/42 (2025.01); A61P 35/00 (2018.01); C12N 5/0636 (2013.01); C12N 5/0638 (2013.01); C12N 2501/2302 (2013.01)] 9 Claims
 
1. A method of treating a cancer disease, comprising:
administering a pharmaceutical composition comprising CD8+ T cells activated by extracellular vesicles derived from CD4+ T cells as an active ingredient to a subject.